Compare Organon & Co. Common Stock (OGN) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Western Alliance Bancorporation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Western Alliance Bancorporation trades at $72.03 (market cap $8.04B). The key difference: Western Alliance Bancorporation is far larger — about 2.2× Organon & Co. Common Stock's market cap, and Western Alliance Bancorporation pays the higher dividend (2.28%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Western Alliance Bancorporation for 3 Days on average.
| OGN | WAL | |
|---|---|---|
Market Cap | $3.62B | $8.04B |
Volume | 2,892,999 | 1,433,355 |
Sector | Health | Financials |
52-Week High | $13.81 | $96.08 |
52-Week Low | $5.70 | $66.70 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $11.04B | $9.57B |
Dividend Yield | 0.58% | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Western Alliance Bancorporation (WAL) trades at $73.73, down 1.29% on the day, reflecting a bearish technical signal despite strong fundamentals. The stock shows solid profitability with a 25.43% net income margin and attractive valuation ratios, including a P/E of 8.32. Recent earnings have mostly beaten estimates, and the company launched WA VenueX, a new financial platform. Analyst consensus is strongly bullish with a $85.09 price target, though technical indicators point to near-term weakness.
The outlook for WAL is positive based on fundamentals and analyst support, but technical headwinds and interest rate sensitivity pose risks. Upside potential exists if the stock rebounds from support levels and executes on growth initiatives, while downside could stem from macroeconomic pressures or missed earnings. The high institutional ownership and recent dividend announcement signal confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
